<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:7fae8603-467a-4660-8bda-926f6d2db6ac,g:0c8c57e3-a52d-4e93-b33c-0c47d38887ad,d:002c5ef899da4a3c89515bcc51de3a87--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>angn-20220302</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N180L2ZyYWc6NzljNDUyOGJkNTUxNDQ1NDg2MWM0MjNhZDY5ZWYyYzAvdGFibGU6OGM5ZDE3MzI5NDQ2NGMzNzgwZDkxZDljOTNkOGMyN2UvdGFibGVyYW5nZTo4YzlkMTczMjk0NDY0YzM3ODBkOTFkOWM5M2Q4YzI3ZV8yLTEtMS0xLTMxODg1_7c281f13-3f33-4d2a-93fd-127e6a4552a4">0001601485</ix:nonNumeric><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N180L2ZyYWc6NzljNDUyOGJkNTUxNDQ1NDg2MWM0MjNhZDY5ZWYyYzAvdGFibGU6OGM5ZDE3MzI5NDQ2NGMzNzgwZDkxZDljOTNkOGMyN2UvdGFibGVyYW5nZTo4YzlkMTczMjk0NDY0YzM3ODBkOTFkOWM5M2Q4YzI3ZV81LTEtMS0xLTMxODg1_44e5da4f-7c6c-469f-a953-ce43b7cade82">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="angn-20220302.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-02</xbrli:startDate><xbrli:endDate>2022-03-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i002c5ef899da4a3c89515bcc51de3a87_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTc2_dd67a6d1-c343-4c2d-803d-0571ab84bc0a">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNzc_ff974db7-4c59-444b-9da3-6e5e5cfccc70">March 2, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:21.5pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTcy_d3e70167-6ab5-4e8b-9ab5-f22ffc81ebd2">ANGION BIOMEDICA CORP.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6NTA5MTY5M2ZiMGFlNDAyNzk5ZmJlOThhZDUwYThmNWQvdGFibGVyYW5nZTo1MDkxNjkzZmIwYWU0MDI3OTlmYmU5OGFkNTBhOGY1ZF8wLTAtMS0xLTMxODg1_fe8c84ad-19d3-4039-9d12-4bf261415de0">Delaware</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6NTA5MTY5M2ZiMGFlNDAyNzk5ZmJlOThhZDUwYThmNWQvdGFibGVyYW5nZTo1MDkxNjkzZmIwYWU0MDI3OTlmYmU5OGFkNTBhOGY1ZF8wLTEtMS0xLTMxODg1_c35f95cf-1f30-43a7-a27b-1fda8fbe2f27">001-39990</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6NTA5MTY5M2ZiMGFlNDAyNzk5ZmJlOThhZDUwYThmNWQvdGFibGVyYW5nZTo1MDkxNjkzZmIwYWU0MDI3OTlmYmU5OGFkNTBhOGY1ZF8wLTMtMS0xLTMxODg1_66ae3373-4a49-42d3-94df-e6740b24cb88">11-3430072</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6NTA5MTY5M2ZiMGFlNDAyNzk5ZmJlOThhZDUwYThmNWQvdGFibGVyYW5nZTo1MDkxNjkzZmIwYWU0MDI3OTlmYmU5OGFkNTBhOGY1ZF8zLTAtMS0xLTMxODg1_201b4554-8af4-4308-85d0-4a8944e647e1">51 Charles Lindbergh Boulevard</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6NTA5MTY5M2ZiMGFlNDAyNzk5ZmJlOThhZDUwYThmNWQvdGFibGVyYW5nZTo1MDkxNjkzZmIwYWU0MDI3OTlmYmU5OGFkNTBhOGY1ZF8zLTEtMS0xLTMxODg1_efd3586e-6c18-4fb6-9b33-a4904a90ea71">Uniondale</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6NTA5MTY5M2ZiMGFlNDAyNzk5ZmJlOThhZDUwYThmNWQvdGFibGVyYW5nZTo1MDkxNjkzZmIwYWU0MDI3OTlmYmU5OGFkNTBhOGY1ZF8zLTItMS0xLTMxODg1_58505d8e-0ce9-4c3b-bfc2-3a1fa28e3fa9">New York</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6NTA5MTY5M2ZiMGFlNDAyNzk5ZmJlOThhZDUwYThmNWQvdGFibGVyYW5nZTo1MDkxNjkzZmIwYWU0MDI3OTlmYmU5OGFkNTBhOGY1ZF8zLTMtMS0xLTMxODg1_5590d2f5-23b0-48f5-94a6-81313a2c9a92">11553</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTc4_91a02c03-469d-4169-b98d-ada7c376ebc0">415</ix:nonNumeric>) <ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTc5_58aaefa8-9354-4652-b62b-7e98eb0ca6ac">655-4899</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTgw_63e143ea-c579-494d-a333-e538c7c34200">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTgx_9ee693eb-baa9-4cb4-a653-1aa9bb7d92f0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTgy_ffdd34ba-cab4-4767-ba12-0eeefa351d64">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTcz_ed46b236-b6d7-4bc7-8e51-b3d52dbc0705">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6ZTYwOWMxY2NlY2U3NGE2ZjlhMDYyYjZlMWZhNmQ3MWUvdGFibGVyYW5nZTplNjA5YzFjY2VjZTc0YTZmOWEwNjJiNmUxZmE2ZDcxZV8xLTAtMS0xLTMxODg1_85e134f6-2fe8-42b3-b693-afaf3a7bdbc1">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6ZTYwOWMxY2NlY2U3NGE2ZjlhMDYyYjZlMWZhNmQ3MWUvdGFibGVyYW5nZTplNjA5YzFjY2VjZTc0YTZmOWEwNjJiNmUxZmE2ZDcxZV8xLTEtMS0xLTMxODg1_b71a3e71-c45d-4fcd-acdc-92f08d327c73">ANGN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGFibGU6ZTYwOWMxY2NlY2U3NGE2ZjlhMDYyYjZlMWZhNmQ3MWUvdGFibGVyYW5nZTplNjA5YzFjY2VjZTc0YTZmOWEwNjJiNmUxZmE2ZDcxZV8xLTItMS0xLTMxODg1_95d31094-b3d5-401f-a6da-657e8e9dcf1f">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xMzEx_2bfd9cc3-782e-43c4-b3f3-c2ad58860a3f">&#9746;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4a0f8a45dab04af28a6dd6f8fb60a22d_D20220302-20220303" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAwMmM1ZWY4OTlkYTRhM2M4OTUxNWJjYzUxZGUzYTg3L3NlYzowMDJjNWVmODk5ZGE0YTNjODk1MTViY2M1MWRlM2E4N18xL2ZyYWc6Y2Q5MDYyNjMzNTYwNDY1ZGI1NTQ3ZTM1Y2FlNjFjZGEvdGV4dHJlZ2lvbjpjZDkwNjI2MzM1NjA0NjVkYjU1NDdlMzVjYWU2MWNkYV8xNTc1_e149effc-13bf-41c6-8a05-dd0fcb90456c">o</ix:nonNumeric></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i002c5ef899da4a3c89515bcc51de3a87_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:109%">Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:109%">Compensation Matters</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">On March 2 and 3, 2022, respectively, the Compensation Committee of the Board of Directors (the &#8220;Board&#8221;) of Angion Biomedica Corp. approved, or the Board approved based upon the recommendations of the Compensation Committee of the Board (the &#8220;Committee&#8221;), 2022 annual base salaries, and equity awards for Angion&#8217;s executive officers (each an &#8220;Executive&#8221;), as set forth below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:109%">2022 Annual Base Salaries and 2021 Cash Bonuses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Approved the following 2022 annual base salaries, to be effective January 1, 2022.  Angion&#8217;s Executives did not receive a 2021 discretionary cash bonus.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Executive</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022 Base Salary</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jay Venkatesan</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">President &amp; Chief Executive Officer</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$608,000.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">John Neylan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Executive Vice President, Chief Medical Officer and Head of Research</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$485,100.00<br/></span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jennifer J. Rhodes</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$440,840.00<br/></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:109%">Equity Awards</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">Approved the following grants of stock options to purchase shares of Angion&#8217;s common stock, pursuant to Angion&#8217;s 2021 Incentive Award Plan, for the Executives listed below.  Such grants reflect annual awards to the listed executives, and an additional enhanced incentive to the executive officers to drive stockholder value in 2022. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:109%">2022 Annual Awards</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Executive</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Shares Subject to Stock Option Granted</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jay Venkatesan</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">President &amp; Chief Executive Officer</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">600,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">John Neylan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Executive Vice President, Chief Medical Officer and Head of Research</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">175,000</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jennifer J. Rhodes</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">175,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Greg Curhan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Financial Officer*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100,000</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">The stock options granted to Dr. Neylan, Ms. Rhodes and Mr. Curhan as an annual award have an exercise price per share of $1.99, the closing price of Angion&#8217;s common stock on the date of grant, March 2, 2022, and vest in equal monthly installments over four years. The stock option granted to Dr. Venkatesan has an exercise price per share of $1.94, the closing price of Angion&#8217;s common stock on the date of grant, March 3, 2022, and vests in equal monthly installments over four years.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:109%">Enhanced Award</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Executive</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Shares Subject to Stock Option Granted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jay Venkatesan</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">President &amp; Chief Executive Officer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">160,000</span></div></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">John Neylan</span></div></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Executive Vice President, Chief Medical Officer and Head of Research</span></div></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100,000</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jennifer J. Rhodes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100,000</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">The stock options granted to Dr. Venkatesan, Dr. Neylan, and Ms. Rhodes as an enhanced award have an exercise price per share of $1.99, the closing price of Angion&#8217;s common stock on the date of grant, March 2, 2022, and vest in equal parts on July 31, 2022 and December 31, 2022, respectively. The stock option granted to Dr. Venkatesan has an exercise price per share of $1.94, the closing price of Angion&#8217;s common stock on the date of grant, March 3, 2022, and vests in equal parts on July 31, 2022 and December 31, 2022, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i002c5ef899da4a3c89515bcc51de3a87_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANGION BIOMEDICA CORP.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Jennifer J. Rhodes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: March 4, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jennifer J. Rhodes</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "angn-20220302.htm", "description": "8-K", "secsgml_size_bytes": 47490}]
{"company-data": {"conformed-name": "Angion Biomedica Corp.", "cik": "0001601485", "assigned-sic": "2834", "irs-number": "113430072", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39990", "film-number": "22714285"}, "business-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553", "phone": "(415) 655-4899"}, "mail-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553"}}
angn-20220302
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
March 2, 2022
Date of Report (date of earliest event reported)
ANGION BIOMEDICA CORP.
(Exact name of registrant as specified in its charter)
Delaware
001-39990
11-3430072
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
51 Charles Lindbergh Boulevard
Uniondale
New York
11553
(Address of Principal Executive Offices)
(Zip Code)
(
415
)
655-4899
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ANGN
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Compensation Matters
On March 2 and 3, 2022, respectively, the Compensation Committee of the Board of Directors (the "Board") of Angion Biomedica Corp. approved, or the Board approved based upon the recommendations of the Compensation Committee of the Board (the "Committee"), 2022 annual base salaries, and equity awards for Angion's executive officers (each an "Executive"), as set forth below.
2022 Annual Base Salaries and 2021 Cash Bonuses
Approved the following 2022 annual base salaries, to be effective January 1, 2022.  Angion's Executives did not receive a 2021 discretionary cash bonus.
Executive
Title
2022 Base Salary
Jay Venkatesan
President & Chief Executive Officer
$608,000.00
John Neylan
Executive Vice President, Chief Medical Officer and Head of Research
$485,100.00
Jennifer J. Rhodes
Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary
$440,840.00
Equity Awards
Approved the following grants of stock options to purchase shares of Angion's common stock, pursuant to Angion's 2021 Incentive Award Plan, for the Executives listed below.  Such grants reflect annual awards to the listed executives, and an additional enhanced incentive to the executive officers to drive stockholder value in 2022.
2022 Annual Awards
Executive
Title
Shares Subject to Stock Option Granted
Jay Venkatesan
President & Chief Executive Officer
600,000
John Neylan
Executive Vice President, Chief Medical Officer and Head of Research
175,000
Jennifer J. Rhodes
Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary
175,000
Greg Curhan
Chief Financial Officer*
100,000
The stock options granted to Dr. Neylan, Ms. Rhodes and Mr. Curhan as an annual award have an exercise price per share of $1.99, the closing price of Angion's common stock on the date of grant, March 2, 2022, and vest in equal monthly installments over four years. The stock option granted to Dr. Venkatesan has an exercise price per share of $1.94, the closing price of Angion's common stock on the date of grant, March 3, 2022, and vests in equal monthly installments over four years.
Enhanced Award
Executive
Title
Shares Subject to Stock Option Granted
Jay Venkatesan
President & Chief Executive Officer
160,000
John Neylan
Executive Vice President, Chief Medical Officer and Head of Research
100,000
Jennifer J. Rhodes
Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary
100,000
The stock options granted to Dr. Venkatesan, Dr. Neylan, and Ms. Rhodes as an enhanced award have an exercise price per share of $1.99, the closing price of Angion's common stock on the date of grant, March 2, 2022, and vest in equal parts on July 31, 2022 and December 31, 2022, respectively. The stock option granted to Dr. Venkatesan has an exercise price per share of $1.94, the closing price of Angion's common stock on the date of grant, March 3, 2022, and vests in equal parts on July 31, 2022 and December 31, 2022, respectively.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANGION BIOMEDICA CORP.
By:
/s/ Jennifer J. Rhodes
Date: March 4, 2022
Jennifer J. Rhodes
Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary